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Abstract
Background: To investigate the surgical outcome of hepatocellular carcinoma (HCC) patients with biliary tumor
thrombi (BTT).
Methods: Surgical outcome of 27 HCC patients with BTT (group I) were compared with randomly selected HCC
patients without BTT (group II; n = 270).
Results: One patient in group I died of hepatic failure within 30 days after resection. The 1-, 3- and 5-year
cumulative survival rates of group I were 70.3%, 25.9%, and 7.4%, respectively; these were significantly lower than
those of group II (90.6%, 54.0%, and 37.7%) (P <0.001). The rates of early recurrence (≤ 1 year) after resection were
significantly higher in group I than group II (70.3% vs. 34.8%) (P < 0.001).
Conclusion: HCC patients with BTT had a worse prognosis after resection than those without BTT. Resection
should be considered for these tumors given the lack of effective alternative therapies.
Background
Hepatocellular carcinoma (HCC), one of the most com-
mon malignancies worldwide, can frequently invade the
portal vein and cause portal vein tumor thrombus. By con-
trast, biliary tumor thrombi (BTT) is rare, and the inci-
dence ranging from 0.53% to 12.9% in autopsy and
surgical specimens [1-4]. HCC patients with BTT have a
poor prognosis. Nonsurgical treatment modalities, such as
transcatheter arterial chemoembolization (TACE), internal
biliary stenting, radiotherapy, often has disappointing out-
comes. Surgical treatment is the only way that possibly
cures the patients. However, the role of hepatic resection
in such patients is controversial [2,5-7].
The aim of the present study was to investigate the
surgical outcome of HCC patients with BTT by compar-
ing with those without BTT.
Methods
Patients
From January 2000 to December 2006, 1246 patients
underwent hepatic resections for HCC, at the Department
of Liver Surgery, the First Affiliated Hospital of Nanjing
Medical University, and Department of Special Treatment
and Liver transplantation in Eastern Hepatobiliary Surgery
Hospital of Second Military Medical University. Among
them, 27 patients were found having BTT (group I).
According to classification proposed by Esaki et al. [8],
three patients (11.1%) had microscopic BTT and 24
patients (88.9%) had macroscopic BTT. For comparison of
surgical results, 270 patients were randomly chosen from
the remaining 1,219 HCC patients without BTT and
matched 10:1 with group I by age, sex, concomitant liver
background, and resection margins (group II).
Routine imaging studies included chest radiography,
abdominal ultrasonography, and abdominal computed
tomography. Endoscopic retrograde cholangiopancreato-
graphy or magnetic resonance cholangiopancreatography
were employed to evaluate the extension of a BTT. Eva-
luation of liver function included serum biochemistry,
prothrombin time. Serum hepatitis B surface antigen
(HBsAg) and hepatitis C antibody were used as the posi-
tive markers of chronic viral hepatitis infection. HCC
was diagnosed by at least two radiologic imaging show-
ing characteristic features of HCC; or one radiologic
imaging showing characteristic features of HCC asso-
ciated with alpha-fetoprotein (AFP) > 400 ng/ml; or
cytologic/histologic evidence [9]. Operative procedures
* Correspondence: zhouyms@yahoo.com.cn
† Contributed equally
2Department of Hepato-Biliary-Pancreato-Vascular Surgery, the First Affiliated
Hospital of Xiamen University, Xiamen, PR China
Full list of author information is available at the end of the article
Shao et al. World Journal of Surgical Oncology 2011, 9:2
http://www.wjso.com/content/9/1/2 WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
© 2011 Shao et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
were determined by preoperative diagnosis of location of
the primary tumors and the extension of BTT.
Tumor size was measured directly in the surgical spe-
cimen by pathology examination. A tumor satellite is
defined as any daughter tumor < 3 cm in size lying
within a 3-cm zone from the dominant tumor [10]. The
histological differentiation of HCC was graded according
to the criteria of Edmondson and Steiner (G1, well dif-
ferentiated; G2, moderately differentiated; G3, poorly
differentiated; G4, undifferentiated) [11]. Macrovascular
invasion was defined as gross invasion of the right or
left main branches of the portal vein or the hepatic
veins [12]. Microvascular invasion indicated the pre-
sence of clusters of cancer cells floating in the vascular
space line by endothelial cells on histopathologic exami-
nation [13]. The diagnosis of liver cirrhosis was based
on the histology.
Perioperative deaths were defined as either within
30 days of surgery or occurring in hospital.
This retrospective study was approved by the ethics
committee of the two hospitals.
Follow-up
After discharge, patients were followed-up every one
month by AFP analysis and ultrasound or computed
tomography at least every three months at our outpati-
ent clinic, especially during the first two years. Patients
who developed recurrence were treated with re-
resection whenever possible, or by TACE, percutaneous
ethanol injection, or radiofrequency ablation as appro-
priate. According to point of recurrences time from the
date of hepatectomy, recurrences were classified into
early (≤ 1 year) and late (> 1 year) recurrences [14].
Statistical analysis
Categorical and continuous variables were compared
with chi-square test and t test, respectively. Overall sur-
vival rates were estimated with the Kaplan-Meier pro-
duct-limit method and compared by log-rank test. All
statistical analyses were performed using SPSS for Win-
dows (version 11.0; SPSS Institute, Chicago, IL, USA).
P < 0.05 was considered statistically significant.
Results
Patients features
The clinical data are presented in Table 1. Compared
with groups II, group I patients had a higher incidence
of carbohydrate antigen19-9 (CA19-9) > 37 U/ml, higher
serum levels of total bilirubin, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), g-glutamyl
transpeptidase (GGT), and alkaline phosphatase (ALP)
(P <0.001). There were no differences in age, sex, serol-
ogy for viral hepatitis, and serum albumin levels among
the two groups. Patients with serum AFP levels greater
than 400 ng/ml were found more frequently in the
group I than in the groups II, but this result did not
reach statistical significance (P = 0.058).
Pathologic features
The pathologic features of HCC patients with or with-
out BTT underwent hepatic resection are shown in
Table 2. The incidence of tumor size ≤ 5 cm tended to
be higher in group I, but this result did not reach sta-
tistical significance (P = 0.091). The incidence of
microscopic vascular invasion, tumor capsule absence,
and high Edmondson- Steiner grade in group I was
significantly higher than that in group II (P <0.05).
There were no significant differences between the two
groups with respect to cirrhosis, resection margins,






Age (years)) 47.1 ± 10.5 48.0 ±11.3 0.272
Sex (Male/Female) 24/3 232/38 0.670
HBsAg-positive 26 (96.7%) 254 (94.1%) 0.636
Anti-HCV-positive 0 2 (1.2%) 0.654
Serum AFP (> 400 ng/ml) 16 (59.3%) 109 (40.3%) 0.058
Serum CA19-9 (> 37 U/ml) 13 (48.1%) 24 (8.8%) < 0.001
Serum total bilirubin (umol/L) 116.4 ± 135.4 14.5 ± 7.8 < 0.001
Serum ALT (IU/L) 132.2 ± 107.9 59.6 ± 53.0 < 0.001
Serum AST (IU/L) 95.58 ± 51.5 60.1 ± 53.8 < 0.001
Serum albumin (g/L) 40.4 ± 4.92 41.8 ± 5.6 0.326
Serum GGT (IU/L) 583.1 ± 372.4 122.9 ± 134.1 < 0.001
Serum ALP (IU/L) 305.4 ± 148.0 132.2 ± 83.1 < 0.001
HBsAg: hepatitis B surface antigen. HCV: hepatitis C virus. AFP: alpha-
fetoprotein.
CA19-9: carbohydrate antigen19-9. BTT: biliary tumor thrombi.
ALT: alanine aminotransferase. AST: aspartate aminotransferase. GGT:
g-glutamyl transpeptidase.
ALP: alkaline phosphatase.
Table 2 Comparison of pathologic features between






Cirrhosis 18 (66.7%) 161 (59.6%) 0.476
Tumor size ≤ 5 cm 17 (62.9%) 124 (41.4%) 0.091
Resection margins ≤ 1 cm 3 (11.1%) 32 (11.8%) 0.909
Macrovascular invasion 3 (11.1%) 26 (9.6%) 0.805
Microvascular invasion 17 (62.9%) 116 (43.0%) 0.046
Lymph node metastasis 1 (3.7%) 8 (2.9%) 0.830
Tumor satellites 5 (18.5%) 42 (15.6%) 0.688
Tumor capsule absence 21 (77.7%) 142 (52.6%) 0.012
Edmonson-Steiner grade
1-2 1 (3.7%) 56 (20.1%) 0.036
3-4 26 (96.3%) 214 (79.9%)
Shao et al. World Journal of Surgical Oncology 2011, 9:2
http://www.wjso.com/content/9/1/2
Page 2 of 5
macroscopic vascular invasion, lymph node metastasis,
and tumor satellites.
Surgical results
The surgical procedures used in group I patients
included right anterior resection (n = 1), right posterior
resection (n = 2), right hepatectomy (n = 4), left hepa-
tectomy (n = 8), left hepatectomy with caudate lobect-
omy (n = 1), left lateral recection (n = 3), left medial
recection (n = 2), and partial resection (n = 6). The
BTT were removed by the choledochotomy in 18 cases,
from the cut end of the bile duct after liver resection in
five cases, and en bloc removal with the primary tumor
in three cases. Extrahepatic bile duct resection and
biliaryenteric anastomosis was performed in one case.
One patient in group I died of hepatic failure within
30 days after resection. There was no perioperative mor-
tality in group II. The 1-, 3- and 5-year cumulative sur-
vival rates of group I were 70.3%, 25.9%, and 7.4%,
respectively; these were significantly lower than those of
group II (90.6%, 54.0%, and 37.7%) (P <0.001) (Figure 1).
During the median follow-up period of 39 months post-
resection (range 1 to 104 months), 25 of patients (92.5%)
in group I and 218 patients (80.7%) in group II experi-
enced intrahepatic recurrence. The rates of early recur-
rence (≤1 year) after resection were significantly higher in
group I than group II (70.3% vs. 34.8%) (P <0.001).
Seven patients in group I recurrenced with BTT again
and had obstructive jaundice. One patient received re-
resection, six were palliated with endoscopic stents.
Discussion
In 1949, Mallory et al. [15] described a single case of
HCC invading the gall bladder and obstructing extra-
hepatic bile ducts. In 1975 Lin et al. [16] described
eight patients and classified icteric type hepatoma.
Since then, there are several reports concerning HCC
with BDT have been published [1-7]. The outcome in
patients who received palliative treatment was poor,
with a mean survival time of less than 5 months
[17-19]. Surgical treatment is the only way that possi-
bly cures the patients [19,20]. However, the resectabil-
ity rate of such tumors was very low in early reports,
ranged only from 2% to 13.2% [21]. In recent years,
with progress in imaging diagnosis and preoperative
management, the number of resectable cases were
increased remarkably [4-7,21].
HCC invades into biliary system through one of the
following three mechanisms: (1) the tumor may grow
continuously in a distal fashion, filling the entire extra-
hepatic biliary system with a solid cast of tumor; (2) a
fragment of necrotic tumor may separate from the prox-
imal intraductal growth, migrating to the distal common
bile duct and causing obstruction; or (3) hemorrhage
from the tumor may partially or completely fill the bili-
ary tree with blood clots [18]. Generally, the tumor
thrombus was not adherent to the bile duct wall so it
could be removed easily. Tumor thrombi rarely invade
the walls of the large bile ducts around the hepatic
hilus. Therefore, liver resection of the involved hepatic
segments with thrombectomy through a choledochot-
omy is a rational technique for curative resection [2].
The indications for extrahepatic bile duct resection were
macroscopic tumor invasion of the large bile ducts
around the hepatic hilus [2].
Venous invasion is a well-established prognostic indi-
cator of HCC [22,23]. By contrast, whether BTT have a
significant impact on the prognosis of HCC remain con-
troversial. Shiomi et al. [2] reported that the 3- and
5-year survival rates were 47% and 28%, respectively, in
17 patients with BTT, similar to those achieved in 115
patients without BTT. Satoh et al. [5] also found that
there were no significant differences in survival between
patients with BTT and those without BTT. These data
suggest that BTT in HCC patients might have lower
aggressive potential and be less important as a prognos-
tic factor. Paradoxically, Yeh et al. [6] in an analysis of
17 patients who underwent resection, reported that the
overall survival was worse in patients with BTT, com-
pared with those without BTT. In another recent study,
Ikenaga et al. [7] reported that the median survival time
of HCC patients with BTT after surgery was signifi-
cantly shorter than that of those without thrombi (11.4
vs. 56.1 months, P = 0.002).
Figure 1 Overall survival of patients in two groups. The overall
survival of group I was lower than group II (P < .001).
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Currently, there are two surgical staging systems,
which were developed based on the analysis of patients
who received hepatic resection: one from the Liver Can-
cer Study Group of Japan (LCSGJ) and another from
the American Joint Committee on Cancer (AJCC)/Inter-
national Union Against Cancer (UICC). In LCSGJ sys-
tem, presence of BTT was considered as an indicator of
“advanced stage” of HCC. A study from Japan reported
that the prognostic stratification ability of the LCSGJ
staging system is superior to that of the AJCC/UICC
staging system and that the BTT is the strongest prog-
nostic factor for HCC [24]. This idea is supported by
the results in our present study showing that the resec-
tion of HCC with BTT results in a significantly worse
survival outcome compared with hepatic resection of
HCC without BTT.
In current study, the incidence of microscopic vascu-
lar invasion [13,23], tumor capsule absence [25,26],
high Edmondson- Steiner grade [22,27,28], and high
level of GGT [29], unfavorable clinical prognostic fac-
tors, in group I were significantly higher than the
respective factors in group II. Therefore, these factors
may account for the poor prognosis in patients with
BTT, at least in part. In addition, the incidences of
CA19-9 > 37 U/ml, elevation of total bilirubin, ALT,
AST, and ALP in group I were significantly higher
than those in group II, which may be related to
obstructive jaundice caused by BTT.
Previous studies have indicated that the HCC patients
with BTT had smaller tumors and a higher percentage
of a tumor size ≤ 5 cm than those without BTT [6].
Similarly, in this study, the incidence of tumor size ≤
5 cm tended to be higher in group I, despite this result
did not reach statistical significance due to the small
number of patients. Although the exact mechanism
remains unknown, some authors have suggested that a
BTT in HCC tends to grow faster than the primary
tumor itself [4].
Tumor recurrence remains the major cause of death
after resection for HCC [30,31]. Despite similar treat-
ments, the prognosis for patients with early recurrence
was worse than that of patients with late recurrence
[14]. Qin et al. [4] reported that 14 patients with BTT
(14/28, 50.0%) were found intrahepatic HCC recurrence
within 1 year after operation. Ikenaga et al. [7] reported
that 53% of patients suffered recurrences in the remnant
liver within 3 months after surgery. In current study,
patients with BTT developed early recurrence after
resection more frequently.
We found seven patients in group I recurrenced with
BTT again. Recurrence in the liver remnant could results
from either intrahepatic metastasis from the primary
tumor or multicentric occurrence. Intrahepatic metasta-
sis is an important mechanism of early intrahepatic
recurrence after resection of HCC. Spreading via the por-
tal vein is considered the main route of intrahepatic
metastasis [14,32]. In current study, 17 patients (62.9%)
in the group I had microscopic vascular invasion. How-
ever, nine of the other ten cases without venous invasion
also developed early recurrence. Similar results had been
published previously by Ikenaga et al. [7], who found that
two patients with BTT without portal vein invasion suf-
fered multiple recurrences in the remnant liver. The
authors speculate that HCC invasion biliary system may
be another route of intrahepatic metastasis.
Esaki et al. [8] reported that HCC patients with
macroscopic BTT had a better postoperative survival
than patients with microscopic BTT. But Ikenaga et al.
[7] found that the prognosis was similar between two
groups. In current study, statistical analysis was limited
by the too small population with microscopic BTT.
The experience with orthotopic liver transplantation
(OLT) in patients with BTT is limited. There were only
five cases reported in the English literatures [21,33]. Of
these patients, one died 20 months after OLT due to
multiple intrahepatic recurrences, one developed carci-
noma recurrence at the lower end of the common bile
duct 27 months after OLT. The other three patients
were alive without evidence of recurrence during the
follow-up period (17.6 to 28.1 months). These results
suggest that OLT may be a treatment option for HCC
with BDT in selected cases.
Conclusions
HCC patients with BTT had a worse prognosis after
resection than those without BTT. Resection should be
considered for these tumors given the lack of effective
alternative therapies. Further studies are needed for
understanding of molecular biology of BTT may yield
therapeutic tools that can improve the prognosis of this
subset of patients.
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